Post-Actavis, FTC Argues Agreement Not To Launch Authorized Generic May Equal Cash Payment
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC seeks to intervene in an antitrust suit alleging Wyeth and Teva’s Effexor XR patent settlement is anticompetitive; the litigation may help determine the scope of the Supreme Court’s ruling in FTC v. Actavis.